OVARIAN CANCER and US: targeted therapy

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label targeted therapy. Show all posts
Showing posts with label targeted therapy. Show all posts

Saturday, March 17, 2012

Future Science - abstract: Targeted cancer therapy: giving histone deacetylase inhibitors



Future Science - Future Medicinal Chemistry - 4(4):505 - Summary

Review
Abstract

Targeted cancer therapy: giving histone deacetylase inhibitors


"Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-molecule therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets. Over 490 clinical trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis – SAHA (vorinostat, Zolinza™) and FK228 (romidepsin, Istodax™). 

However, the current HDACis have serious limitations, including ineffectively low concentrations in solid tumors and cardiac toxicity, which is hindering their progress in the clinic. Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution."

Saturday, January 07, 2012

not yet recruiting: Integrated Molecular Profiling in Advanced Cancers Trial - breast, non-small cell lung, colorectal, ovarian, phase 1 (patients) - Full Text View - ClinicalTrials.gov UHN (Toronto)



 Advanced cancer
Advanced breast, non-small cell lung, colorectal and ovarian cancers; as well as patients who are phase I trial candidates
 
Purpose
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.
Biomarkers are specific characteristics of the cancer that may help provide prognostic information (i.e. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.
The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, in order to help their physicians to identify which clinical trials of molecularly targeted therapies may be most appropriate for the patient in the future.
Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT)
This study is not yet open for participant recruitment.
Verified on January 2012 by University Health Network, Toronto

First Received on January 4, 2012.   Last Updated on January 5, 2012   History of Changes
Sponsor: University Health Network, Toronto
Collaborator: Princess Margaret Hospital, Canada
Information provided by (Responsible Party): University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT01505400

Tuesday, June 28, 2011

June 3rd: Personalized Therapy Benefits Late-Stage Cancer Patients in Clinical Trial - Cancerwise | Cancer blog from MD Anderson Cancer Center



"Researchers analyzed tumors of 1,144 patients with metastatic or inoperable cancer. Their median age was 58, and the median number of prior treatments was four. Of these, 460 had one or more gene defects targetable by available approved or experimental drugs."

Wednesday, August 04, 2010

Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary



Take home message: Annexin A4 enhances cancer cell chemoresistance and is overexpressed in tumors of patients with ovarian CCC. Targeting of annexin A4 may represent a future strategy to counteract resistance to chemotherapy in ovarian CCC.